Abstract
Aim & objective: Levormeloxifene (L-ORM) and raloxifene (RAL) are selective estrogen receptor modulators used in the treatment of postmenopausal osteoporosis and breast cancer. Here, we developed and validated a liquid chromatography-tandem mass spectrometry (LC–MS/MS) method for the simultaneous estimation of both drugs. Materials & methods: A quality-by-design (QbD) approach was used for the optimization of the nanoemulsion, and US FDA guidelines were followed for method validation. Results: Multiple reaction monitoring transitions were used for L-ORM (459.05→98.50), RAL (475.00→112.02) and internal standard (180.10→110.2). Analytes were resolved in a C18 column with 80:20 v/v% acetonitrile (ACN), 0.1% formic acid in triple-distilled water as a mobile phase. The developed method was linear over a concentration range of 1–600 ng/ml. Pharmacokinetic results of free L-ORM–RAL and the L-ORM–RAL nanoemulsion showed Cmax of free L-ORM – 70.65 ± 16.64, free RAL 13.53 ± 2.72, L-ORM nanoemulsion 65.07 ± 14.0 and RAL-nanoemulsion 59.27 ± 17.44 ng/ml. Conclusion: Future findings will contribute to the treatment of postmenopausal osteoporosis and breast cancer using L-ORM and RAL.
Graphical abstract
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Clinical update on osteoporosis. J. Midwifery Womens Health 64(3), 265–275 (2019).
- 2. . Drug insight: existing and emerging therapies for osteoporosis. Nat. Clin. Pract. Endocrinol. Metab. 2(12), 670–680 (2006).
- 3. . Long-term treatment of postmenopausal osteoporosis. Endocrinol. Metab. (Seoul) 36(3), 544–552 (2021).
- 4. . Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin. Ther. 28(2) 151–173 (2006). •• Describes advanced options for the treatment of postmenopausal osteoporosis.
- 5. . Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am. J. Obstet. Gynecol. 187(3), 521–527 (2002).
- 6. Simultaneous estimation of raloxifene and cladrin by HPLC: application to metabolic stability studies in different species. Bioanalysis 15(11) 601–620 (2023). • Describes the simultaneous estimation of raloxifene and cladrin using high-performance liquid chromatography (HPLC).
- 7. . Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clin. Interv. Aging 5(1), 19–29 (2010). •• Selective estrogen receptor modulators used for the treatment of osteoporosis in postmenopausal women.
- 8. . Effects of estrogen, raloxifene, and levormeloxifene on the expression of Rho-kinase signaling molecules in urethral smooth muscle cells. Urology 76(6), 1517.e6–1517.e11 (2010).
- 9. Pharmacokinetic interaction potential assessment of cladrin, a potent bioactive constituent of Butea monosperma, and raloxifene, a prescription anti-osteoporotic by in vitro ADME approach. Indian J. Tradit. Knowl. 21(4), 789–796 (2022). •• Describes the in vitro absorption, distribution, metabolism and excretion profile of antiosteoporotic agents.
- 10. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause 28(9), 973–997 (2021).
- 11. . Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys. Bone 29(1), 7–15 (2001).
- 12. LC–MS/MS method for simultaneous estimation of raloxifene, cladrin in rat plasma: application in pharmacokinetic studies. Bioanalysis 16(3), 141–153 (2024).
- 13. . Raloxifene as a treatment option for viral infections. J. Microbiol. 59(2), 124–131 (2021).
- 14. . Benefit–risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf. 28(8), 721–730 (2005).
- 15. Drug design targeting protein–protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J. Med. Chem. 57(3), 632–641 (2014). • Study explaining the protein interaction by using multiple ligand simultaneous docking and also describing the discovery of raloxifene and bazedoxifene.
- 16. . Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator. Br. J. Clin. Pharmacol. 53(3), 284–295 (2002). •• Levormeloxifene used as a new selective estrogen receptor modulator in postmenopausal women.
- 17. . Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Climacteric 22(2), 140–147 (2019).
- 18. . Raloxifene as treatment for various types of brain injuries and neurodegenerative diseases: a good start. Int. J. Mol. Sci. 21(20), 1–31 (2020).
- 19. . The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease – chronic kidney disease – mineral and bone disorder: osteoporosis. J. Chin. Med. Assoc. 76(7), 365–371 (2013).
- 20. . Estrogen therapy for osteoporosis in the modern era. Osteoporos. Int. 29(5), 1049–1055 (2018).
- 21. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos. Int. 31(12), 2271–2286 (2020).
- 22. . Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat. Drug Metab. Dispos. 28(5), 503–513 (2000).
- 23. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337(23), 1641–1647 (1997).
- 24. . Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 287(0607), 847–857 (2015).
- 25. . A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits. Arterioscler. Thromb. Vasc. Biol. 17(10), 2264–2272 (1997).
- 26. . Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J. Clin. Endocrinol. Metab. 86(2), 755–760 (2015).
- 27. . Development and validation of a liquid chromatography–tandem mass spectrometry assay for determination of raloxifene and its metabolites in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 855(2), 220–227 (2007).
- 28. Development and validation of ultra-high-performance liquid chromatography–mass spectrometry method for the determination of raloxifene and its phase II metabolites in plasma: application to pharmacokinetic studies in rats. J. Sep. Sci. 43(24), 4414–4423 (2020).
- 29. . Oral bioavailability enhancement of raloxifene with nanostructured lipid carriers. Nanomaterials 10(6), 1–17 (2020).
- 30. . Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry. J. Pharm. Biomed. Anal. 126, 83–97 (2016). •• Discusses the guidelines for bioanalytical method validation.
- 31. . LC–MS/MS method for determination of non-opioid analgesics adulterants in herbal medicines. Chem. Afr. 5(6), 2149–2162 (2022).
- 32. Simultaneous assessment of ciprofloxacin and dexamethasone in ocular tear fluid by LC–MS/MS: application to a pharmacokinetic study in rabbits. Chin. J. Analyt. Chem. 51(6), 100197 (2023).
- 33. Pharmacokinetics and bioavailability assessment of miltefosine in rats using high performance liquid chromatography tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1031, 123–130 (2016). • Describes the pharmacokinetic profile of miltefosine in rats using liquid chromatography-tandem mass spectrometry (LC–MS/MS).
- 34. . Validation of bioanalytical LC–MS/MS assays: evaluation of matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(23), 2198–2207 (2009).
- 35. . Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC–MS/MS. Anal. Chem. 75(13), 3019–3030 (2003).
- 36. . Ultrasonically tailored, chemically engineered and ‘quality by design’ enabled fabrication of agomelatine nanoemulsion; optimization, characterization, ex-vivo permeation and stability study. Ultrason. Sonochem. 41, 213–226 (2018). • Study describing the quality-by-design approach for the optimization of nanoformulations.
- 37. . Reinvestigating nanoprecipitation via Box–Behnken design: a systematic approach. J. Microencapsulation 32(1), 75–85 (2015).
- 38. Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response. J. Control. Rel. 196, 295–306 (2014).
- 39. Formulation, characterization and antimicrobial properties of black cumin essential oil nanoemulsions stabilized by OSA starch. J. Food Sci. Technol. 54(10), 3358–3365 (2017).
- 40. Fabrication and evaluation of quercetin nanoemulsion: a delivery system with improved bioavailability and therapeutic efficacy in diabetes mellitus. Pharmaceuticals 15(1), 70 (2022).
- 41. . Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo. Int. J. Nanomed. 10, 3737–3750 (2015).
- 42. HPLC method for simultaneous estimation of paclitaxel and baicalein: pharmaceutical and pharmacokinetic applications. Bioanalysis 14(14), 1005–1020 (2022). •• Simultaneous estimation of paclitaxel and baicalein using HPLC and its applicability in pharmacokinetic studies.
- 43. . Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal. Int. J. Nanomed. 7, 3787–3802 (2012).
- 44. Paclitaxel-loaded colloidal silica and TPGS-based solid self-emulsifying system interferes Akt/mTOR Pathway in MDA-MB-231 and demonstrates anti-tumor effect in syngeneic mammary tumors. AAPS PharmSciTech 21(8), 1–18 (2020).
- 45. . Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer. Int. J. Nanomed. 12, 645–658 (2017).
- 46. Ratiometric codelivery of paclitaxel and baicalein loaded nanoemulsion for enhancement of breast cancer treatment. Int. J. Pharm. 643(3), 123209 (2023).
- 47. Enhanced apoptosis and mitochondrial cell death by paclitaxel-loaded TPP-TPGS1000-functionalized nanoemulsion. Nanomedicine 18(4), 343–366 (2023). • Study describing the codelivery of paclitaxel- and baicalein-loaded nanoemulsion for the treatment of breast cancer.
- 48. . The pharmacokinetics of raloxifene and its interaction with apigenin in rat. Molecules 15(11), 8478–8487 (2010).
- 49. . Therapeutic effect of centchroman alone and in combination with glycine soya on 7,12-dimethylbenz[α]anthracene-induced breast tumor in rat. Food Chem. Toxicol. 48(6), 1587–1591 (2010).